Another blow has been dealt to the field of Alzheimer’s research as MSD announces yet another trial failure of a drug to treat the disease. The firm halted development of the drug Verubecestat after it could not present enough potential efficacy in prodromal forms of the condition to warrant further study.
The decision was made following a recommendation from the external Data Monitoring Committee, which advised that a positive benefit/risk was unlikely to be achieved by continuing the trial.
